There were 1,507 press releases posted in the last 24 hours and 392,808 in the last 365 days.

ADM Tronics Accepted for Membership in MTEC - Medical Technology Enterprise Consortium

Northvale, NJ, Nov. 08, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- ADM Tronics Unlimited, Inc. (OTCQB: ADMT) has been accepted for membership in the Medical Technology Enterprise Consortium (“MTEC”), a 501(c)3 biomedical technology consortium collaborating with multiple government agencies to foster integrated research partnerships to speed availability of medical technology solutions to the military, veterans and the civilian population.

ADMT’s expertise in the research, development and commercialization of therapeutic and diagnostic innovative medical device technologies aligns with the mission and goals of MTEC.  MTEC membership is comprised of a wide range of organizations, including large companies, small businesses, academic research institutions and non-profit organizations.  MTEC facilitates collaboration among its members and government agencies on biomedical research and development across all areas of military medicine.

“We are pleased to now be part of MTEC and look forward to opportunities to apply our medical technology development capabilities and experience to help optimize the health and performance of America’s active duty and military veterans,” stated Andre’ DiMino, President of ADMT.

As previously announced, ADMT is currently in development of three of its own proprietary therapeutic medical technologies which could have application in military medicine.  These include the Alvio™ Respiratory Therapy platform; the Aurex-3® tinnitus treatment modality; and, the Sonotron® musculoskeletal pain therapy system.  

On October 15, 2018 ADMT announced that it has completed development and engineering to bring the Alvio™ respiratory technology into production ready status with the initial 100-unit production run being assembled now.  These initial Alvio production units are slated for user and clinic testing, including testing at the Mayo Clinic under the direction of Dr. Bruce Johnson.  Dr. Johnson has dedicated his research to improving treatment of patients with pulmonary conditions.  Research prototypes of the Alvio platform were previously successfully evaluated in Dr. Johnson’s lab. 

In addition to its own technologies, ADMT has developed medical device technologies for third-party customers which may also have application in military biomedical research and development.

“The diverse areas of medical technology areas we have been involved with over many years gives us a broad base of experience in electronic biomedical technologies which we believe can be very helpful in potential collaborations developed through our membership in MTEC,” commented Mr. DiMino.

For more information on MTEC visit and view a video at

About ADMT

ADMT is a diversified, technology-based developer and manufacturer of innovative technologies and products.  Its core competency is its ability to conceptualize a technology, bring it through development, into manufacturing and commercialization, all in-house.  ADMT has three areas of activity: Medical Device Design, Engineering, Regulatory and Manufacturing Services; Proprietary Electronic Medical Devices; and Eco-Friendly, Water-Based Formulations.  The Company’s headquarters, laboratories, FDA-Registered medical device and manufacturing operations are in Northvale, NJ.  ADMT’s multi-disciplinary team of engineers, researchers and technologists utilize advanced technology infrastructure, such as 3-D prototyping, precision instrumentation and specialized software and peripherals, for research, development and commercialization of diversified technologies. Additional information is available at the Company’s website

Except for historical information contained herein, the matters set forth in this news release are “forward looking” statements (as defined in the Private Securities Litigation Reform Act of 1995), including statements regarding future revenue growth and performance.  Although ADMT believes the expectations reflected in such forward looking statements are based upon reasonable assumptions, there can be no assurance that its expectations will be realized. Forward looking statements involve risks and uncertainties that could cause actual results to differ materially from expectations.  Factors that could contribute to such differences include those described from time to time in ADMT’s SEC filings, news releases and other communications. The Company assumes no obligation to update information contained in this news release.


Andre’ DiMino